NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$155.52

-3.99 (-2.50%)

(As of 11:27 AM ET)

Compare

Today's Range: $154.00
▼
$161.72
50-Day Range: $159.51
▼
$225.77
52-Week Range: $57.21
▼
$322.67

Volume: 113,134 shs
Average Volume: 365,194 shs
Market Capitalization: $2.87 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $309.18

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 93.8% Upside
$309.18 Price Target
Short Interest: Bearish
15.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: 0.46
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($18.77) to ($8.98) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

146th out of 965 stocks

Pharmaceutical Preparations Industry

50th out of 452 stocks

4.4

Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $309.18, Madrigal Pharmaceuticals has a forecasted upside of 93.8% from its current price of $159.51.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
15.15% of the float of Madrigal Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Madrigal Pharmaceuticals has recently increased by 8.29%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Madrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Madrigal Pharmaceuticals is -0.92.

1.9

News and Social Media Coverage

News Sentiment
Madrigal Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Madrigal Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 16 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.86% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($18.77) to ($8.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 13.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Price History

30 days | 90 days | 365 days | Advanced Chart

MDGL Stock News Headlines

September 21, 2023 | msn.com

Obesity treatment optimism boosts Eli Lilly, Novo Nordisk while others face downturn

September 20, 2023 | finance.yahoo.com

1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

September 20, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Given "Outperform" Rating at Evercore ISI

September 20, 2023 | americanbankingnews.com

Analysts Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) PT at $309.18

September 20, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 19, 2023 | msn.com

Evercore ISI Group Maintains Madrigal Pharmaceuticals (MDGL) Outperform Recommendation

September 15, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 22, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 14, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 13, 2023 | msn.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Jumps on Move to the Head of the FDA Line

September 13, 2023 | marketwatch.com

Madrigal Gets FDA Priority Review of Resmetirom in NASH With Liver Fibrosis >MDGL

September 13, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

September 13, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line

September 13, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Reaffirmed by HC Wainwright

September 12, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals' (MDGL) Neutral Rating Reaffirmed at B. Riley

September 11, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Madrigal Pharmaceuticals

September 11, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

September 11, 2023 | benzinga.com

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

September 7, 2023 | finance.yahoo.com

3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of

September 1, 2023 | markets.businessinsider.com

B.Riley Financial Sticks to Its Hold Rating for Madrigal Pharmaceuticals (MDGL)

August 23, 2023 | finance.yahoo.com

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

August 20, 2023 | msn.com

Madrigal's Resmetirom Nears Commercialization Despite Market Concerns

August 14, 2023 | finance.yahoo.com

John Paulson's Q2 2023 13F Filing Update

August 10, 2023 | seekingalpha.com

Madrigal Pharmaceuticals: The NASH Market Is No Longer Guaranteed

August 8, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

August 8, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

See More Headlines

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings: 8/08/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MDGL
CUSIP: 87162T20
CIK: 1157601
Web: www.madrigalpharma.com
Phone: (267) 824-2827
Fax: 781-274-8228
Employees: 92
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $309.18
High Stock Price Forecast: $390.00
Low Stock Price Forecast: $224.00
Forecasted Upside/Downside: +93.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.82
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($18.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-295,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -285.72%
Return on Assets: -114.11%

Debt

Debt-to-Equity Ratio: 0.96
Current Ratio: 3.02
Quick Ratio: 3.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.54 per share
Price / Book: 13.82

Miscellaneous

Outstanding Shares: 18,470,000
Free Float: 14,053,000
Market Cap: $2.95 billion
Optionable: Optionable
Beta: -0.72

Social Links

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Rebecca A. Taub M.D. (Age 71)
Founder, Chief Medical Officer, Pres of R&D and Director
Comp: $939.83k

Mr. Alex G. Howarth (Age 54)
Sr. VP & CFO
Comp: $757.26k

Mr. Brian J. Lynch J.D. (Age 61)
Sr. VP & Gen. Counsel
Comp: $763.75k

Mr. Remy Sukhija (Age 51)
Sr. VP & Chief Commercial Officer
Comp: $785.2k

Mr. William J. Sibold (Age 57)
CEO & Director

Dr. Kianoush Motesharei Ph.d. (Age 53)
Sr. VP of Bus. & Corp. Devel.

Mr. Edward Chiang
Sr. VP of Clinical & Technical Operations

Mr. Thomas W. Hare
Sr. VP of Clinical Management

Dr. Robert E. Waltermire Ph.D. (Age 59)
Chief Pharmaceutical Devel. Officer

Dr. Stephen Dodge M.B.A.
Pharm.D., Sr. VP of Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.
What is Madrigal Pharmaceuticals' stock price forecast for 2023?: 11 brokerages have issued twelve-month price objectives for Madrigal Pharmaceuticals' stock. Their MDGL share price forecasts range from $224.00 to $390.00. On average, they predict the company's stock price to reach $309.18 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.
How have MDGL shares performed in 2023?: Madrigal Pharmaceuticals' stock was trading at $290.25 at the start of the year. Since then, MDGL stock has decreased by 45.0% and is now trading at $159.51.
View the best growth stocks for 2023 here.
When is Madrigal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MDGL earnings forecast.
How were Madrigal Pharmaceuticals' earnings last quarter?: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($4.69) earnings per share for the quarter, missing the consensus estimate of ($4.59) by $0.10.
What ETFs hold Madrigal Pharmaceuticals' stock?: ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Alger Mid Cap 40 ETF (FRTY), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Pharmaceuticals ETF (IHE).Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Madrigal Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).
What is Madrigal Pharmaceuticals' stock symbol?: Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
Who are Madrigal Pharmaceuticals' major shareholders?: Madrigal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.65%), State Street Corp (2.94%), Assenagon Asset Management S.A. (2.55%), Marshall Wace LLP (2.49%), Alliancebernstein L.P. (2.01%) and Perceptive Advisors LLC (1.64%). Insiders that own company stock include Brian Joseph Lynch, Remy Sukhija and Richard S Levy.
View institutional ownership trends.
How do I buy shares of Madrigal Pharmaceuticals?: Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Madrigal Pharmaceuticals' stock price today?: One share of MDGL stock can currently be purchased for approximately $159.51.
How much money does Madrigal Pharmaceuticals make?: Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $2.95 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.65) on an earnings per share basis.
How can I contact Madrigal Pharmaceuticals?: Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

Madrigal Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

MDGL Price History

MDGL Stock News Headlines

MDGL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MDGL Stock - Frequently Asked Questions

Overall MarketRank^™